Galectin Therapeutics (GALT) Share-based Compensation (2010 - 2026)
Galectin Therapeutics (GALT) posted quarterly Share-based Compensation of $686000.0 for Q1 2026, up 46.58% year-over-year from $468000.0 in Q1 2025, and up 674.45% quarter-over-quarter from $88579.0 in Q4 2025.
Powered by 
Analysis
Galectin Therapeutics (GALT) Share-based Compensation (2010 - 2026) Analysis & Trends
Galectin Therapeutics' Share-based Compensation history runs 17 years deep, the most recent figure standing at $686000.0 for Q1 2026.
- In Q1 2026, Share-based Compensation rose 46.58% year-over-year to $686000.0; the TTM figure through Mar 2026 stood at $1.7 million (down 13.89% YoY), while the FY2025 annual figure was $1.7 million, down 32.33% from the prior year.
- Share-based Compensation for Q1 2026 stood at $686000.0, up from $88579.0 in the prior quarter.
- The five-year high for Share-based Compensation was $1.0 million in Q2 2025, with the low at $72000.0 in Q1 2024.
- The 5-year median for Share-based Compensation is $515000.0 (2024), against an average of $479257.0.
- The sharpest annual moves came in 2023 and 2025: Share-based Compensation tumbled 86.95% in 2023, then jumped 550.0% in 2025.
- Galectin Therapeutics' Share-based Compensation stood at $178000.0 in 2022, then decreased by 12.17% to $156345.0 in 2023, then soared by 92.17% to $300445.0 in 2024, then sank by 70.52% to $88579.0 in 2025, then jumped by 674.45% to $686000.0 in 2026.
- Business Quant data shows GALT's Share-based Compensation at $686000.0 in Q1 2026, $88579.0 in Q4 2025, and $498000.0 in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Share-based Compensation (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.51 Bn | 130.66 Bn | 2.84 Bn | 108.10 Mn |
| 2 | Regeneron Pharmaceuticals | 85.24 Bn | 77.25 Bn | 3.93 Bn | 243.00 Mn |
| 3 | Argenx Se | 63.46 Bn | 58.28 Bn | 1.37 Bn | - |
| 4 | Moderna | 57.89 Bn | 52.75 Bn | 52.00 Mn | 120.00 Mn |
| 5 | Revolution Medicines | 44.02 Bn | 44.02 Bn | - | 277.20 Mn |
| 6 | BeOne Medicines | 39.95 Bn | 34.85 Bn | 1.53 Bn | 137.41 Mn |
| 7 | Alnylam Pharmaceuticals | 35.49 Bn | 32.19 Bn | 992.69 Mn | 86.63 Mn |
| 8 | Royalty Pharma | 28.43 Bn | 27.59 Bn | - | - |
| 9 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 41.25 Mn |
| 10 | Galectin Therapeutics | 305.66 Mn | 305.66 Mn | - | 7.03 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 7.03 Mn |
| Mar 31, 2026 | 7.21 Mn |
| Dec 31, 2025 | 88,579.00 |
| Sep 30, 2025 | 7.33 Mn |
| Jun 30, 2025 | 7.54 Mn |
| Mar 31, 2025 | 8.00 Mn |
| Dec 31, 2024 | 300,445.00 |
| Sep 30, 2024 | 7.31 Mn |
| Jun 30, 2024 | 7.37 Mn |
| Mar 31, 2024 | 7.40 Mn |
| Dec 31, 2023 | 156,345.00 |
| Sep 30, 2023 | 6.43 Mn |
| Jun 30, 2023 | 6.29 Mn |
| Mar 31, 2023 | 6.53 Mn |
| Dec 31, 2022 | 681,000.00 |
| Sep 30, 2022 | 5.65 Mn |
| Jun 30, 2022 | 5.65 Mn |
| Mar 31, 2022 | 5.63 Mn |
| Dec 31, 2021 | 654,000.00 |
| Sep 30, 2021 | 4.66 Mn |